Retatrutide at EASD 2026: TRIUMPH-2 Data, EloraTZP and What Comes Next

What Did Eli Lilly Announce on 15 September 2026?

Eli Lilly announced on 15 September 2026 that it will present new data across its cardiometabolic portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held in Milan, Italy from 28 September to 2 October 2026.[1] The centrepiece for retatrutide (LY3437943) research is a dedicated, EASD-sponsored symposium on Wednesday, 30 September, presenting full Phase 3 results from TRIUMPH-2 — the trial in adults with obesity/overweight and type 2 diabetes.

It is worth being precise about what is and is not new here. Lilly already disclosed TRIUMPH-2's topline figures in a press release on 23 July 2026, which we covered at the time.[2] The 15 September announcement is not a fresh readout; it confirms that the full underlying dataset will be presented to the diabetes research community for the first time, in the format researchers rely on for scrutiny — slides, discussant commentary and typically a simultaneous or near-simultaneous peer-reviewed publication, none of which a topline press release provides.

What Will the TRIUMPH-2 Symposium Show?

These are the same headline numbers reported in July, restated in Lilly's EASD preview. What changes at a medical-conference symposium is depth: the topline release gave weight and A1C endpoints and a short discontinuation table; a symposium presentation typically adds fuller subgroup breakdowns (by baseline A1C, weight class, background diabetes medication), a more granular adverse-event profile, and the discussion of limitations that independent researchers use to judge a trial's external validity. Until the presentation and any accompanying publication are public, the subgroup and safety detail below the topline remains unconfirmed.

What Is EloraTZP, and Does It Compete With Retatrutide?

Alongside TRIUMPH-2, Lilly's EASD announcement confirmed it will unveil Phase 2 data for eloraTZP, an investigational combination of eloralintide — a selective amylin receptor agonist — and tirzepatide, Lilly's marketed GIP/GLP-1 receptor agonist.[1] The Phase 2 study is registered as NCT06603571, evaluating eloralintide alone and in combination with tirzepatide in adults with obesity or overweight, with and without type 2 diabetes.[3]

EloraTZP is mechanistically distinct from retatrutide, and the contrast is useful for anyone tracking incretin-pathway research. Retatrutide is a single molecule built to agonise three receptors — GLP-1, GIP and glucagon — at once. EloraTZP instead pairs two separate agents, adding amylin-receptor agonism on top of tirzepatide's existing dual GIP/GLP-1 action. Earlier Phase 1 data reported that adding eloralintide 3 mg to tirzepatide 5 mg produced 17% weight loss at 16 weeks, versus 10% for tirzepatide 5 mg alone.[4] Lilly is now pursuing both a single-molecule triple-agonist strategy and a combination-therapy strategy in parallel, which is itself a signal worth noting for anyone modelling where incretin pharmacology research is heading next.

What About Foundayo's ACHIEVE-4 Data?

The same EASD announcement covers ACHIEVE-4, which Lilly describes as its largest and longest study to date of Foundayo (orforglipron), its oral non-peptide GLP-1 receptor agonist, in type 2 diabetes.[1] No specific ACHIEVE-4 efficacy figures were disclosed in the 15 September preview; those are expected at the meeting itself, running 28 September to 2 October. For background on Foundayo's UK regulatory position, see our Foundayo/orforglipron guide.

Does This Change Retatrutide's Regulatory Timeline?

No. The 15 September announcement is a conference-presentation schedule, not a regulatory filing update, and it states no change to Lilly's plan — set out in its 23 July 2026 release — to submit a Biologics License Application (BLA) for retatrutide to the FDA in Q1 2027. See our FDA approval timeline guide for the fuller regulatory picture. Major diabetes and obesity trial data is often paired with simultaneous peer-reviewed publication at large meetings such as EASD, but Lilly's preview did not name a specific journal, so that remains unconfirmed until the meeting.

What Should UK Researchers Take From This?

Nothing here changes retatrutide's UK regulatory status: it remains an unlicensed, investigational compound with no MHRA marketing authorisation, and nothing in this article constitutes a therapeutic or health claim. Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, with no health or therapeutic claims made for it.

This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions